Home > Dermatology > AAD 2018 > Pearls of the posters > Better gastrointestinal tolerability with biologics than the conventional therapy

Better gastrointestinal tolerability with biologics than the conventional therapy

Conference
AAD 2018

In Switzerland, consenting patients with moderate-to-severe psoriasis enter the SDNTT (Swiss Dermatology Network for Targeted Therapies) Psoriasis Registry when they start systemic treatment. The purpose of adding the outpatient data to the non-interventional registry lies in obtaining long-term evidence for the efficacy and safety of these therapies in psoriasis and comparing adverse and serious adverse events between biological and non-biological drugs.

In the evaluation presented, 473 patients were included until December 2016: this corresponds to 264 patient years of biological and 272 years of non-biological systemic therapy [1]. Their mean age was 46.7 years, 65% were male and more than a third not only suffered from psoriasis but also from psoriatic arthritis.

Rates of serious adverse events and non-serious infection rates were not significantly different between the two treatment groups. The most reported non-serious adverse events were ineffectiveness of th...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on